```html

Junctional Tumor of the Small Bowel (Peutz‑Jeghers Syndrome)

Overview

Junctional tumor of the small bowel is a rare, premalignant lesion that occurs at the transition (junction) between the mucosal lining and the submucosa of the small intestine. In the context of Peutz‑Jeghers syndrome (PJS), these lesions are most often hamartomatous polyps that have the potential to progress to adenocarcinoma or other gastrointestinal (GI) cancers.

• Who it affects: Individuals with a confirmed genetic diagnosis of Peutz‑Jeghers syndrome. PJS is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50 % chance of inheriting the mutation.
• Prevalence: PJS occurs in approximately 1 in 25,000–30,000 live births worldwide. Junctional tumors are detected in roughly 10‑20 % of PJS patients during routine surveillance, but the exact incidence is uncertain because many lesions are asymptomatic and identified only on endoscopy or imaging.
• Typical age of presentation: Polyps can develop in childhood, but junctional tumors most often become apparent in the second to fourth decade of life.

Understanding the natural history of these tumors is essential because early detection dramatically reduces the risk of progression to invasive cancer.

Symptoms

Junctional tumors may be silent for years. When symptoms appear, they are usually related to the size, location, or complications of the polyp.

• Abdominal pain or cramping – often intermittent and related to partial obstruction.
• Intestinal obstruction – severe, colicky pain with vomiting and inability to pass gas or stool.
• Gastrointestinal bleeding – may present as melena (black, tarry stools), hematochezia (bright red blood per rectum), or occult blood detected on testing.
• Iron‑deficiency anemia – fatigue, pallor, shortness of breath due to chronic slow bleeding.
• Weight loss – unintended loss caused by malabsorption or reduced intake from fear of pain.
• Intussusception – “telescoping” of one bowel segment into another, leading to acute abdomen.
• Perforation – very rare; sudden severe pain, guarding, and signs of peritonitis.
• Visible mucocutaneous pigmentation – characteristic dark spots on lips, oral mucosa, hands, and feet, a hallmark of PJS that alerts clinicians to the underlying syndrome.

Because many symptoms overlap with other GI conditions, a high index of suspicion is needed when a patient with PJS reports any of the above.

Causes and Risk Factors

Genetic Basis

Peutz‑Jeghers syndrome is caused by pathogenic variants in the STK11/LKB1 tumor‑suppressor gene located on chromosome 19p13.3. Loss of STK11 function leads to uncontrolled cell growth in the gastrointestinal epithelium, producing hamartomatous polyps that can undergo dysplastic change at the mucosal‑submucosal junction.

Risk Factors Specific to Junctional Tumors

• Family history of PJS – the most powerful predictor.
• Number and size of polyps – patients with >10 polyps or polyps >1 cm have a higher likelihood of malignant transformation.
• Age – risk rises after the age of 20, with a peak incidence of cancer between 30–50 years.
• Environmental factors – smoking, heavy alcohol use, and chronic inflammation (e.g., Crohn’s disease) may accelerate dysplasia, although data are limited.

Other Syndromic Associations

Rarely, junctional tumors can appear in individuals with other hamartoma‑related syndromes (e.g., Cowden syndrome) due to overlapping pathways involving PTEN and mTOR signaling.

Diagnosis

Because early lesions are often asymptomatic, surveillance is the cornerstone of diagnosis.

Screening Protocols

• Video capsule endoscopy (VCE) – non‑invasive visualization of the entire small bowel; sensitivity >90 % for polyps ≥5 mm.
• Double‑balloon enteroscopy (DBE) – allows direct visualization, biopsy, and therapeutic removal of polyps.
• Magnetic Resonance Enterography (MRE) – assesses larger polyps, obstruction, and extra‑luminal disease without radiation.
• CT enterography – used when urgent evaluation for obstruction or perforation is needed.

Histopathology

Biopsy of a suspicious lesion typically shows a hamartomatous architecture with a characteristic “arborizing” smooth‑muscle core. Dysplasia or carcinoma in situ is identified by nuclear atypia, increased mitoses, and loss of normal polarity at the mucosal‑submucosal junction.

Genetic Testing

Confirmatory testing for STK11 mutations is recommended for all suspected PJS cases and for first-degree relatives. Testing can be performed via targeted gene panels, whole‑exome sequencing, or multiplex ligation‑dependent probe amplification (MLPA) to detect large deletions.

Lab Studies

• Complete blood count (CBC) – to detect anemia.
• Serum iron studies – ferritin, transferrin saturation.
• Tumor markers (CEA, CA 19‑9) – not routinely diagnostic but may be useful in surveillance for malignant transformation.

Treatment Options

Treatment is individualized based on polyp size, location, symptoms, and presence of dysplasia.

Endoscopic Polypectomy

• Cold snare or hot snare polypectomy – preferred for polyps ≤2 cm.
• Endoscopic mucosal resection (EMR) – for larger lesions that can be lifted with submucosal injection.
• Success rates exceed 95 % for removing polyps without perforation when performed by experienced endoscopists.

Surgical Intervention

• Laparoscopic segmental resection – indicated for polyps causing obstruction, intussusception, or those with high‑grade dysplasia.
• Enterotomy with “polyp‑sparing” removal – removes multiple polyps through a limited incision, preserving bowel length.

Pharmacologic Approaches

• mTOR inhibitors (e.g., sirolimus, everolimus) – emerging data suggest they may reduce polyp burden in animal models; clinical trials are ongoing (NCT03910284).
• COX‑2 inhibitors (e.g., celecoxib) – modest polyp size reduction reported in small case series, but cardiovascular risk must be weighed.

Lifestyle & Supportive Care

• Iron supplementation for anemia.
• High‑protein, high‑calorie diet if malabsorption is present.
• Smoking cessation and limiting alcohol to decrease additional cancer risk.

Surveillance After Treatment

Even after removal, polyps can recur. Guidelines from the American College of Gastroenterology (2022) recommend:

• Video capsule endoscopy every 2–3 years for adults.
• Upper and lower endoscopy every 3 years, or more often if polyps are found.
• Lifelong annual physical exam with attention to mucocutaneous pigmentation changes.

Living with Junctional Tumor of the Small Bowel (Peutz‑Jeghers Syndrome)

Daily Management Tips

• Maintain a symptom diary – record abdominal pain, bleeding episodes, or changes in bowel habits.
• Adhere to surveillance schedule – missing an endoscopic exam can allow a polyp to grow unchecked.
• Nutrition – aim for a balanced diet rich in iron (lean meats, leafy greens), calcium, and vitamin D to counteract potential malabsorption.
• Hydration – adequate fluid intake helps prevent constipation and reduces stricture risk.
• Physical activity – regular moderate exercise supports gastrointestinal motility.
• Genetic counseling – discuss family planning and testing for relatives.
• Psychosocial support – connect with PJS patient groups or counseling services to manage anxiety about cancer risk.

What to Expect at Medical Appointments

During routine visits, physicians will review your symptom log, perform a focused abdominal exam, and may order blood work or imaging. Be prepared to discuss any new pigmented spots, as changes can signal evolving disease.

Prevention

While the underlying genetic mutation cannot be altered, several actions can lower the chance of malignant transformation:

• Early and regular surveillance – catches polyps before they become large or dysplastic.
• Prompt removal of polyps ≥1 cm – reduces mechanical complications and cancer risk.
• Healthy lifestyle – avoid tobacco, limit alcohol, maintain a healthy weight.
• Vaccinations – Hepatitis B and HPV vaccination lower the risk of liver and cervical cancers, which are also increased in PJS.
• Medical prophylaxis – participation in clinical trials of mTOR inhibitors may become preventive therapy in the future.

Complications

If left untreated, junctional tumors can lead to serious outcomes:

• Intestinal obstruction – may require emergency surgery.
• Intussusception – especially common in children with large polyps.
• Bleeding and severe anemia – can necessitate blood transfusions.
• Perforation – life‑threatening intra‑abdominal infection.
• Malignant transformation – up to 15 % of PJS patients develop small‑bowel adenocarcinoma, with a 5‑year survival of 30–40 % if diagnosed late (source: NIH Cancer.gov).
• Secondary cancers – increased risk of breast, pancreatic, ovarian, and lung cancers; comprehensive cancer screening is recommended.

When to Seek Emergency Care

References

• Mayo Clinic. “Peutz‑Jeghers syndrome.” https://www.mayoclinic.org (accessed May 2026).
• American College of Gastroenterology. “Guidelines for Surveillance of Patients with Peutz‑Jeghers Syndrome.” Gastroenterology, 2022.
• National Cancer Institute. “Peutz‑Jeghers Syndrome Treatment (PDQ®)” https://www.cancer.gov.
• World Health Organization. “Genetic and Rare Diseases Information.” WHO Fact Sheet, 2021.
• Cleveland Clinic. “Intussusception in Adults.” https://my.clevelandclinic.org.
• ClinicalTrials.gov. “Sirolimus for Reducing Polyp Burden in Peutz‑Jeghers Syndrome.” NCT03910284.
• CDC. “Vaccines for Cancer Prevention.” https://www.cdc.gov.

```